FDA OKs diabetes drug combo Jentadueto

01/30/2012 | Wall Street Journal, The

Eli Lilly and Co. and Boehringer Ingelheim received FDA approval for Jentadueto, a type 2 diabetes medicine intended for use with exercise and diet. The oral treatment, which combines linagliptin and metformin hydrochloride, can be taken alone or with commonly prescribed sulfonylurea.

View Full Article in:

Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Attest Health Care Advisors
Nationwide, SL_Nationwide
Biotechnology/Pharmaceutical Patent Attorney
Coats and Bennett PLLC
Cary, NC
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Food Lawyer
Wayzata, MN
Meridian Health Plan
Detroit, MI